New Chromatography Resin Developed for Secretory Antibodies

Why It Matters

The technology paves the way for scalable production of secretory IgA therapeutics, addressing a growing demand for mucosal immunity treatments and improving bioprocess economics.

Key Takeaways

• New resin specifically captures IgA at commercial‑grade titers
• Ligand mimics Protein A, binds bacterial surface molecules
• Macropore design separates 400 kDa IgA from 70‑80 kDa impurity
• Simplifies downstream filtration, reducing processing steps
• Optimization aims to match Protein A’s functional performance

Pulse Analysis

Secretory antibodies, particularly IgA, have attracted renewed interest after the COVID‑19 pandemic highlighted the importance of mucosal immunity for respiratory and gastrointestinal diseases. Unlike conventional monoclonal antibodies, IgA’s larger, dimeric structure and associated secretory component pose unique purification challenges that have limited its commercial rollout. By delivering a resin that can isolate fully assembled IgA at gram‑per‑liter concentrations, BOKU researchers address a critical bottleneck, potentially unlocking a new class of therapeutics for conditions ranging from chronic lung infections to inflammatory bowel disease.

The core of the new resin is a synthetic ligand derived from a bacterial surface protein, engineered to exhibit high affinity for the Fc region of IgA. Its macroporous architecture provides sufficient pore size to accommodate the 400 kDa IgA molecule while allowing the smaller secretory component—often the dominant impurity—to flow through. This design mirrors the well‑established Protein A capture step used for IgG, but with specificity tuned to IgA’s distinct structural features. The result is a single capture‑and‑filter operation that reduces downstream polishing steps, cuts resin costs, and improves overall yield, making large‑scale manufacturing more economically viable.

If the ongoing ligand optimization succeeds in matching Protein A’s binding capacity and robustness, the resin could become a standard platform for secretory antibody production. Such a breakthrough would accelerate clinical development pipelines, attract investment into mucosal vaccine and therapy programs, and expand the biopharma market beyond traditional systemic antibodies. However, scale‑up will require validation of resin longevity, cleaning‑in‑place compatibility, and regulatory acceptance, all of which will determine how quickly the technology translates into commercial bioprocesses.